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Abstract
Background: Increasing evidence elucidating the pathogenic mechanisms of ulcerative colitis (UC)
has accumulated and the disease is widely assumed to be the consequence of genetic susceptibility
and an abnormal immune response to commensal bacteria. However evidence regarding an
infectious etiology in UC remains elusive.
Case presentation: We report a provocative case of UC with profound rheumatologic
involvement directly preceded by Clostridium difficile infection and accompanying fever, vomiting,
bloody diarrhea, and arthritis. Colonic biopsy revealed a histopathology suggestive of UC.
Antibiotic treatment eliminated detectable levels of enteric pathogens but did not abate symptoms.
Resolution of symptoms was procurable with oral prednisone, but tapering of corticosteroids was
only achievable in combination therapy with vancomycin and metronidazole.
Conclusions: An infectious pathogen may have both precipitated and exacerbated autoimmune
disease attributes in UC, symptoms of which could be resolved only with a combination of
corticosteroids, vancomycin and metronidazole. This may warrant the need for more perceptive
scrutiny of C. difficile and the like in patients with UC.
Background
Clostridium difficile infection may be a compounding fac-
tor in ulcerative colitis (UC) with data suggestive of a role
in disease exacerbation or initiation by the organism in a
subset of patients [1]. Adjunctive antibiotic therapy, either
broad-spectrum or gram positive-specific, has shown lim-
ited efficacy in UC [2,3]. However, sporadic reports in
which significant therapeutic potential was achieved [4-6]
suggest that a distinct subclass of patients with an infec-
tious-associated phenotype may exist. Although there
have been an increasing number of case reports on ulcer-
ative colitis complicated by cytomegalovirus infection [7-
9], there are few with conclusive evidence of infection
with Clostridium difficile. Herein, we report a case of ster-
oid-resistant UC with profound rheumatologic involve-
ment immediately preceded by C. difficile infection in
which remission of UC symptoms was twice achieved in
response to adjunct metronidazole and vancomycin ther-
apy. The patient remained symptom-free without sup-
portive therapy for a four-year period.
Case presentation
A 32-year-old white male presented with nausea, vomit-
ing, crampy lower abdominal pain and diarrhea. His
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hematocrit 45.8% (40–54%), sodium 131 mEq/l (135–
146 mEq/l), potassium 3.9 mEq/l (3.5–5.5 mEq/l), bicar-
bonate 24 mEq/l (22–24 mEq/l), chloride 91 mEq/l (95–
112 mEq/l), BUN 37 mg/dl (7–25 mg/dl), serum creati-
nine 1.6 mg/dl (0.7–1.4 mg/dl), and normal liver func-
tion tests. He was treated with intravenous fluids,
Ciprofloxacin and anti-emetics, to which the diarrhea
resolved in 2–3 days. After one month he had recurrent
watery diarrhea accompanied with rectal pain, bleeding
and vomiting. He also developed fever of 101.6 F.
The physical exam was remarkable for decreased bowel
sounds and moderate lower abdominal tenderness. There
were no masses or organomegalies palpable. The rectal
exam was remarkable for tenderness and heme-positive
mucus. The remainder of the physical exam was unevent-
ful. Stool samples from the initial visit were positive for
Clostridium difficile cytotoxin, and depicted many WBCs
(neutrophils 99% and eosinophils 1%), suggesting an
infectious etiology. Stool sample was negative for giardia
lamblia, salmonella, shigella, campylobacter, aeromonas
and plesiomonas. There was no predominance of staphy-
lococcus, yeast, or pseudomonas.
The patient was initially started on Ciprofloxacin (500 mg
bid.) for 3 days without symptom resolution. Metronida-
zole was added (250 mg tid.), but intolerance of the
patient to metronidazole with exacerbations of nausea
prompted the replacement to Vancomycin (250 mg qid)
in conjunction with Ciprofloxacin for 7 days. During this
initial treatment period, the patient characteristically
developed migratory polyarticular joint pain and swelling
involving the shoulders, elbows, fingers, hips and knees.
Lack of response to antibiotics suggested an autoimmune
disease as a contributing factor.
At this time a sigmoidoscopy and pinch biopsy revealed
diffuse acute and chronic inflammation with cryptitis,
mucin depletion, and glandular foreshortening and
branching suggestive of UC (Fig. 1). The patient was
treated with Asacol (400 mg bid.) in conjunction with
metronidazole (250 mg qid). After 7 days of combined
therapy with continued weight loss and no improvement,
prednisone (60 mg qid.) was added, resulting in cessation
of GI symptoms and moderate improvement in joint pain
and swelling. After 7 days of continued improvement, the
antibiotic and Asacol therapy were stopped. The patient
was maintained on high dose steroids for 14 days. How-
ever, fever, gastrointestinal, and joint symptoms recurred
upon tapering of prednisone to 20 mg a day. When symp-
toms recurred, a stool culture was negative for infectious
agents including Clostridium difficile antigen, confirming
an autoimmune component to disease pathology in this
patient. Prednisone was increased to 30 mg per day at
which point gastrointestinal symptoms resolved but joint
swelling and pain continued. Over the course of 3 months
prednisone tapering was attempted three additional
times, with each resulting in symptom recurrence.
After 3 months of treatment, the patient experienced an
acute dental abscess and was prescribed a combination
vancomycin (250 mg tid) and metronidazole (250 mg
tid). During this period, the patient was able to gradually
reduce prednisone dosage without symptom recurrence.
Antibiotics were continued for 30 days during which time
prednisone was tapered completely. Symptoms did not
recur and the patient remained symptom-free without fur-
ther therapeutic intervention for 4.5 years.
After this prolonged period of remission of UC symp-
toms, a second episode similar to the first occurred. The
patient once again presented with bloody diarrhea, nau-
sea, vomiting, and joint pain. Stool cultures were Clostrid-
ium difficile positive by culture and cytotoxin. Once again
the patient was treated with 60 mg daily of prednisone
and metronidazole (250 mg tid). Symptoms did not
resolve, and vancomycin (125 mg tid) was added, result-
ing in a significant improvement in symptoms. After 2
weeks of combined therapy metronidazole treatment was
stopped and symptoms recurred within a week. Metroni-
dazole was once again added, leading to resolution of
symptoms. Combined antibiotic and steroid therapy con-
tinued for 2 months during which time prednisone was
tapered completely and a second remission of UC symp-
toms was induced.
Discussion
The patient was remarkable in several regards. The onset
of UC and spondyloarthropathy coincided with C. difficile
infection. While various therapeutic regimens of pred-
nisone, vancomycin and metronidazole preceded a nega-
tive C. difficile toxin test, remission of UC symptoms
could only be induced by the combination of these three
medications. C. difficile toxin tests have shown varying
efficacy in diagnosing pseudomembranous colitis. It has
been demonstrated that toxin-negative patients with C.
difficile positive stool culture may still have symptomatic
pseudomembranous colitis [10]. Lynch et al showed that
46% of stool specimens from patients test negative by
cytotoxin but positive by culture [11]. Likewise, others
have shown that some cases of C. difficile infection cannot
be detected by the cytotoxin assay and suggested that the
organism has the ability to vary toxin production [12-16].
The bacterium also tends to persist as an antibiotic-resist-
ant vegetative spore, which explains the high frequency at
which the symptoms recur following treatment.
Since toxin-negative patients have presented with C. diffi-
cile related diarrhea, it is reasonable to assume that thePage 2 of 5
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patient, but especially in a patient with inflammatory
bowel disease (IBD). The elusiveness of the bacterium in
diagnosis of C. difficile infected IBD patients was con-
firmed in 2001 by Markowitz et al. They demonstrated
that single-toxin assays failed to identify C. difficile infec-
tion in approximately 40% of pediatric IBD patients and
in a case report where a toxin A positive, toxin B negative
variant was detected [14,17]. It has also been shown that
IBD patients have a higher incidence of C. difficile infec-
tion than in healthy controls [18]. When considered
together with the case reported here, this information
leads us to the hypothesis that a small subclass of UC
pathology may actually have an infectious etiology result-
ing from chronic C. difficile infection.
IBD has been shown to be more prevalent in industrial-
ized nations, where antibiotic treatment has its longest
history [19]. The increase in IBD prevalence parallels ris-
ing antibiotic use over the last 50 years [20]. If an undetec-
ted antibiotic-resistant enteric pathogen is responsible for
inducing or exacerbating IBD, then widespread antibiotic
use may have contributed to the increased prevalence of
IBD in these industrialized nations.
Colonic mucosal inflammation in ulcerative colitis with loss of goblet cells and neutrophilic infiltrate (magnification ×100)Figure 1
Colonic mucosal inflammation in ulcerative colitis with loss of goblet cells and neutrophilic infiltrate (magnification ×100)Page 3 of 5
(page number not for citation purposes)
BMC Gastroenterology 2005, 5:3 http://www.biomedcentral.com/1471-230X/5/3This case is especially interesting considering H. pylori and
its recently discovered tendency to adhere to glycoconju-
gates expressed in inflamed gastric mucosa [21]. In light of
this new information, it is tempting to speculate that C.
difficile could similarly bind to inflamed colonic tissue in
this subclass of UC patients. Further research in this area
could yield valuable new data.
The potential utility of combined therapy is further sug-
gested by the fact that antimicrobial resistance among C.
difficile strains to metronidazole and with intermediate
resistance to vancomycin is emerging in countries like
Hong Kong (where one of 100 C. difficile isolates was
resistant to metronidazole) and Spain (where 9% of 469
clinically significant C. difficile isolates were resistant to
metronidazole, particularly in isolates recovered from
HIV-positive patients and few patients also had interme-
diate resistance to vancomycin) [22-24] It is interesting to
note that no resistance was found to metronidazole or
vancomycin among C. difficile strains from isolates in
patients from UK, Germany, Brazil, Poland or Kuwait [25-
29]. The Public Health Laboratory Service (PHLS) Anaer-
obe Reference Unit (ARU) has also not been successful in
detection of metronidazole resistance in any of their over
1000 C. difficile isolates tested [24]. The impact of drug
resistance should be considered if long-term treatment is
utilized in patients. However, a complicating factor in this
context is that for metronidazole and vancomycin, mini-
mum inhibitory concentration susceptibility breakpoints
are usually set for isolates causing systemic infections that
are based upon antimicrobial levels in blood (serum) and
not on the levels in the intraluminal area, where higher
drug concentrations can be achieved [30].
Conclusions
Recurrent relapses could only be suppressed in this
patient by the combination therapy of corticosteroids,
metronidazole and vancomycin. Our observations sug-
gest that this combination therapy may be effective to
confront and induce remissions of UC symptoms in
patients with C. difficile toxin-positive refractory autoim-
mune symptomatologic UC as opposed to the use of a sin-
gle agent.
An opportunistic C. difficile infection commonly results
from the use of broad-spectrum antibiotics like quinolo-
nes. The frequent use of these antibiotics in treating IBD
suggests that these patients could develop C. difficile infec-
tion during treatment, thereby exacerbating symptoms
and preventing remission of UC symptoms. It may there-
fore be practical to probe for C. difficile infections more
meticulously in patients with IBD.
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